Puig announced on 14 September that it will buy Esteve's 50% stake in Isdin for €1.2bn, taking full ownership of the Spanish dermocosmetics and sun care business. Source: https://en.ara.cat/economy/puig-buys-50-of-isdin-from-esteve-for-1-200-million_1_5849804.html, with further detail from Cosmetics Business at https://cosmeticsbusiness.com/puig-take-full-ownership-isdin-deepen-dermocosmetics.
The terms are specific. €900m in cash at closing. A further €300m as a fixed deferred payment, with no interest, in the first quarter of 2029. Closing is expected by the end of the first quarter of 2027, subject to competition approvals. Puig will fund it from its own resources and debt.
Puig's CEO José Manuel Albesa said expanding in dermocosmetics is a strategic priority. Executive chairman Marc Puig described Isdin as "five decades of shared vision between the Puig and Esteve families" and a company with "a distinctive position at the intersection of science and beauty". Isdin's CEO Juan Naya said the business will stay focused on "serving health care professionals and consumers".
That last phrase is the one to hold onto.
What is actually being bought
Isdin is a dermatology-focused brand. Its reputation was not built on a viral launch or a founder's following. It was built over decades, in a channel where the person recommending the product is a professional whose own credibility is on the line every time they do it.
That is a very particular kind of asset. A pharmacist who tells a customer with sensitive skin which sunscreen to use is not being paid per post. A dermatologist who writes a brand name on a piece of paper is putting their clinical judgement behind it. Once a brand is trusted in that way, the recommendation repeats, patient after patient, customer after customer, without a media budget attached to each one.
When a buyer pays €1.2bn for half a business like this, the formulas are part of it, and so is the manufacturing. But the thing that took fifty years and cannot be reproduced by a competitor with a large cheque is the professional trust. Anyone can hire chemists. Nobody can hire two generations of pharmacists' goodwill.
Why the large groups are moving here now
Puig's move is not isolated. The reporting frames it as a way to increase its skin care exposure, and Investing.com's coverage connected it to fragrance demand normalising and pressure on Middle East travel retail. Puig had also been in merger talks with Estée Lauder that ended earlier this year, so this is a group actively looking for where its next growth comes from.
The answer it chose is a category where trust is earned through evidence and professionals, not through attention. For large groups that is attractive because it is defensible. Attention can be bought by any competitor willing to spend. A recommendation habit inside a professional channel is much harder to dislodge.
For a smaller brand, this is useful information about where value sits when the time comes to sell, or to raise. The brands that command strategic interest in skin care are increasingly the ones with proof and professional backing, rather than the ones with the loudest launch.
The professional channel is slow, and that is the point
The honest thing to say to a founder is that this route is slow. Getting in front of dermatologists, aestheticians, pharmacists or skin clinics takes time, samples, education and patience. None of them will recommend a product because it is trending. They will recommend it because they have seen it work and they understand why.
That slowness is exactly why it is worth something. A channel that is quick to enter is quick for competitors to enter too. A channel that takes years to earn protects the brands that put the years in.
It also changes what a brand has to be. Professionals ask different questions from consumers. What is the active, at what concentration, what is the evidence, who tested it, on what skin, over how long, and what are the known sensitivities. A brand that cannot answer those clearly will not get past the first conversation, however beautiful the packaging.
The structure is worth studying too
The deal terms carry a lesson of their own. Puig is not paying €1.2bn on the day. It is paying €900m at closing and €300m more than two years later, without interest.
That is a large, sophisticated buyer acquiring a business it has co-owned for decades, and it still chose to defer a quarter of the price. Deferred consideration is a normal feature of how deals are built, not a sign of distrust.
For founders this matters because the headline number in any exit conversation is rarely the number that arrives at completion. Earn-outs, deferred payments, working capital adjustments and conditions all sit between the two. It is common for a founder to anchor on the headline and be disappointed by the cash at closing.
The practical habit is to model every offer as two figures: what you receive on the day, and what you receive later if everything goes to plan. Then ask what could stop the second figure arriving, and how much of that is within your control.
What a £500k to £5m brand can actually take from this
Nobody reading this is about to become Isdin. But the principle scales down well.
First, build the evidence file before you need it. For each claim you make on pack or on your site, keep the underlying study, the methodology, the sample size and the duration in one place. If a professional asks, you should be able to send it the same day. If you cannot, the claim is weaker than you think.
Second, start one professional relationship, not twenty. A single aesthetician, clinic or independent pharmacy that genuinely uses and recommends your product teaches you more about the professional channel than a trade show stand. Learn what they ask, what they need and what makes them comfortable putting their name near yours.
Third, be careful with the language of the category. Dermatologist-developed, clinically proven and similar phrases carry real weight with professionals and with regulators. Use them only when the evidence underneath is solid, because in this channel one overreaching claim can close a door for years.
Fourth, track recommendations as a metric. Ask new customers how they heard about you, and record when the answer is a professional. It is a small number at first. It is also the number a strategic buyer in this category will eventually want to see.
The plain version
Puig has agreed to pay €1.2bn for the half of Isdin it did not already own, with €300m of that deferred to 2029. The group says dermocosmetics is a strategic priority.
What it is buying is a business that professionals have trusted for decades. That trust is slow to build, hard to copy and very valuable once it exists. For a small brand it is also the one form of growth that gets more defensible, rather than more expensive, the longer you do it.